Shimla Online

Esophageal Cancer Pipeline, Clinical Trial Analysis and NDA Approvals | 80+ Companies and 80+ Drugs

 Breaking News
  • No posts were found

Esophageal Cancer Pipeline, Clinical Trial Analysis and NDA Approvals | 80+ Companies and 80+ Drugs

January 18
18:48 2023
Esophageal Cancer Pipeline, Clinical Trial Analysis and NDA Approvals | 80+ Companies and 80+ Drugs

DelveInsight’s, “Esophageal Cancer Pipeline Insight, 2023” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Esophageal Cancer pipeline landscape. It covers the Esophageal Cancer pipeline drug profiles, including Esophageal Cancer clinical trial and nonclinical stage products. It also covers the Esophageal Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Esophageal Cancer pipeline products in this space.

 

In the Esophageal Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Esophageal Cancer clinical trial studies, Esophageal Cancer NDA approvals (if any), and product development activities comprising the technology, Esophageal Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Key takeaways from the Esophageal Cancer Pipeline Report

  • DelveInsight’s Esophageal Cancer pipeline analysis depicts a robust space with 80+ active players working to develop 80+ pipeline therapies.
  • The leading Esophageal Cancer Companies are working to develop potential drug candidates to improve the Esophageal Cancer treatment scenario include BeiGene, AstraZeneca, CSPC ZhongQi Pharmaceutical Technology, Amgen, Jiangsu Hengrui Medicine, Oncolys Biopharma, Pfizer, Novartis, Luye Pharma, Eli Lilly and Company, ImmunoFrontier, Inc, Adaptimmune, Innovent Biologics (Suzhou) Co. Ltd., Genentech, Janssen Pharmaceuticals, Merck KGaA, Shenzhen Hornetcorn Biotechnology, Apexigen, Inc., Highlight Therapeutics, EMD Serono, HaiHe Biopharma, Shenzhen BinDeBio Ltd., Lumicell, Jacobio Pharmaceuticals Co., Ltd., TESARO, Ascentage Pharma Group Inc., Guangdong Xiangxue Precision Medical Technology, CytomX Therapeutics, Shionogi, Guangdong Zhongsheng Pharmaceutical Co., Ltd., VM Oncology, LLC, Dragonfly Therapeutics, TG Therapeutics, AVEO Pharmaceuticals, OncoTherapy Science, Sorrento Therapeutics, Incyte Corporation, Roche, Henlix Biotech, Athenex, Biostage, Celldex Therapeutics, Kymab Limited, NGM Biopharmaceuticals, Seagen Inc., Novita Pharmaceuticals, ADC Therapeutics S.A., Arcus Biosciences, Inc., Sinocelltech Ltd., Sunshine Lake Pharma, Jiangsu Alphamab Biopharmaceuticals, CStone Pharmaceutical, Ipsen, Atreca, and others.
  • Promising Esophageal Cancer pipeline therapies such as Tislelizumab, Durvalumab, Mitoxantrone liposomal, Panitumumab, SHR-1210, OBP-301, Apatinib, Sunitinib malate, RAD001, Irinotecan, Ramucirumab, IMF-001, Autologous genetically modified ADP-A2M4CD8 cells, Sintilimab, Atezolizumab, Erdafitinib, M6620, DC-CIK, APX005M, BO-112, M1231, Ramucirumab, CYH33, PCA062, CAR-T/TCR-T cells, LUM015, JAB-3068, Niraparib, APG-2449, TAEST16001, CX-2029, S-488210, ZSP1241, VMD-928 300, DF6002, TGR-1202, AV 203, S-588410, Socazolimab, AMG 337, Retifanlimab, RO 7092284, Serplulimab, Cellspan Esophageal implant, CDX-1140, KY1044, NGM120, SGN-B6A, NP-G2-044, ADCT-301, AB308, Epacadostat, SCT-I10A, Larotinib, KN046, Sugemalimab, and others.
  • The Esophageal Cancer Companies and academics are working to assess challenges and seek opportunities that could influence Esophageal Cancer R&D. The Esophageal Cancer pipeline therapies under development are focused on novel approaches to treat/improve Esophageal Cancer.
  • Esophageal Cancer pipeline report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery.

 

To explore more information on the latest breakthroughs in the Esophageal Cancer treatment landscape of the report, click here @ Esophageal Cancer Pipeline Outlook

 

Recent Developmental Activities in the Esophageal Cancer Treatment Landscape

  • In September 2020, BeiGene announced that the U.S. Food and Drug Administration (FDA) accepted to review a Biologics License Application (BLA) for their anti-PD-1 antibody tislelizumab to treat patients with unresectable recurrent locally advanced or metastatic Esophageal Squamous Cell Carcinoma (ESCC). July 12, 2022, is the Prescription Drug User Fee Act (PDUFA) target action date.
  • CX-2029, co-developed by CytomX and AbbVie is a PDC directed against CD71, the transferrin receptor which is highly expressed on a number of solid and hematologic tumors, including diffuse large B-cell lymphoma and also Esophageal Cancer.
  • Telomelysin (OBP-301) is a gene-modified oncolytic adenovirus that selectively replicates in cancer cells by introducing human telomerase reverse transcriptase (hTERT) promoter. A Japanese pharmaceutical company Chugai Pharmaceutical is conducting phase 2 study, based on the exclusive license agreement for Telomelysin concluded between Chugai and Oncolys on 8 April, 2019.
  • Zymeworks’ lead product candidate, zanidatamab, is a HER2-targeted bispecific antibody developed using Zymeworks proprietary Azymetric™ platform. Zanidatamab has been granted Fast Track designation for first-line gastroesophageal adenocarcinoma in combination with standard of care chemotherapy.
  • In May 2020, Rafael Pharmaceuticals Enters into Research Collaboration with Roswell Park Comprehensive Cancer Center to Evaluate the Effects of CPI-613® (Devimistat) on Esophageal Cancer.
  • Nanobiotix is evaluating NBTXR3 in Phase I clinical trial. The trial was conducted as a part of an ongoing clinical collaboration at The University of Texas MD Anderson Cancer Center (MD Anderson).

 

Esophageal Cancer Overview

Esophageal cancer develops in the esophagus, which is the tube that connects throat to the stomach. Tumors arise in the mucosa, which is the inner lining of the esophagus. There are two types of esophageal cancer, each with different risk factors: Adenocarcinoma -Cancers that start in gland cells at the bottom of the esophagus are called adenocarcinomas. This type of cancer is the most common esophageal cancer. It usually occurs closer to the stomach. Chronic acid reflux, gastroesophageal reflux disease (GERD), Barrett’s esophagus and chronic heartburn can increase the risk of developing adenocarcinoma esophageal cancer.

 

Request a sample and discover the recent advances in Esophageal Cancer Ongoing Clinical Trial Analysis and Medications, click here @ Esophageal Cancer Treatment Landscape

 

Esophageal Cancer Emerging Drugs Profile

 

AN-0025: Adlai Nortye

AN0025 is a clinical stage, potential first-in-class EP4 antagonist designed to modulate tumor microenvironment. It blocks the PGE2-EP4 signaling pathway to inhibit PGE2-mediated immunosuppression in the tumor microenvironment. Currently, the drug is in Phase I stage of Clinical trial evaluation for the treatment of Esophageal Cancer.

 

Tucatinib: Seagen

Tucatinib (TUKYSA®) is an oral medicine that is a tyrosine kinase inhibitor of the HER2 protein, a protein that contributes to cancer cell growth.HER2 is overexpressed in multiple cancers, including breast, colorectal, and gastric cancers. In preclinical in vitro studies, TUKYSA inhibited phosphorylation of HER2 and HER3, resulting in inhibition of downstream MAPK and AKT signaling and cell growth (proliferation), and showed anti-tumor activity in HER2-expressing tumor cells. In preclinical and clinical studies, TUKYSA inhibited the growth of HER2-expressing tumors. The combination of TUKYSA and the anti-HER2 antibody trastuzumab has also been shown to increase anti-tumor activity in vitro and in vivo compared to either medicine alone. Currently, the drug is in Phase II/III stage of Clinical trial evaluation for the treatment of Esophageal Cancer.

 

APX 005M: Apexigen

APX005M is a novel, humanized monoclonal antibody that stimulates the anti-tumor immune response. APX005M targets CD40, a co-stimulatory receptor that is essential for activating both innate and adaptive immune systems. Binding of APX005M to CD40 on antigen presenting cells (i.e., dendritic cells, monocytes and B-cells) initiates a multi-faceted immune response bringing multiple components of the immune system (e.g., T cells, macrophages) to work in concert against cancer. APX005M is currently in Phase 2 clinical development for the treatment of cancers such as pancreatic cancer, esophageal and gastroesophageal junction cancers, melanoma, non-small cell lung cancer, rectal cancer and sarcoma in various combinations with immunotherapy, chemotherapy, radiation therapy or a cancer vaccine.

 

Esophageal Cancer Therapeutics Assessment

There is approx. 80+ key companies which are developing the therapies for Esophageal Cancer. The companies which have their Esophageal Cancer drug candidates in the most advanced stage, i.e. phase II/III include, Seagen.

 

For further information, refer to the detailed Esophageal Cancer Unmet Needs, Esophageal Cancer Market Drivers, and Esophageal Cancer Market Barriers, click here @ Esophageal Cancer Ongoing Clinical Trial Analysis

 

Esophageal Cancer Phases

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Esophageal Cancer Pre-clinical and Discovery stage candidates
  • Esophageal Cancer Discontinued & Inactive candidates

 

Scope of the Esophageal Cancer Pipeline Report

  • Coverage- Global
  • Esophageal Cancer CompaniesBeiGene, AstraZeneca, CSPC ZhongQi Pharmaceutical Technology, Amgen, Jiangsu Hengrui Medicine, Oncolys Biopharma, Pfizer, Novartis, Luye Pharma, Eli Lilly and Company, ImmunoFrontier, Inc, Adaptimmune, Innovent Biologics (Suzhou) Co. Ltd., Genentech, Janssen Pharmaceuticals, Merck KGaA, Shenzhen Hornetcorn Biotechnology, Apexigen, Inc., Highlight Therapeutics, EMD Serono, HaiHe Biopharma, Shenzhen BinDeBio Ltd., Lumicell, Jacobio Pharmaceuticals Co., Ltd., TESARO, Ascentage Pharma Group Inc., Guangdong Xiangxue Precision Medical Technology, CytomX Therapeutics, Shionogi, Guangdong Zhongsheng Pharmaceutical Co., Ltd., VM Oncology, LLC, Dragonfly Therapeutics, TG Therapeutics, AVEO Pharmaceuticals, OncoTherapy Science, Sorrento Therapeutics, Incyte Corporation, Roche, Henlix Biotech, Athenex, Biostage, Celldex Therapeutics, Kymab Limited, NGM Biopharmaceuticals, Seagen Inc., Novita Pharmaceuticals, ADC Therapeutics S.A., Arcus Biosciences, Inc., Sinocelltech Ltd., Sunshine Lake Pharma, Jiangsu Alphamab Biopharmaceuticals, CStone Pharmaceutical, Ipsen, Atreca, and others.
  • Esophageal Cancer Pipeline Therapies- Tislelizumab, Durvalumab, Mitoxantrone liposomal, Panitumumab, SHR-1210, OBP-301, Apatinib, Sunitinib malate, RAD001, Irinotecan, Ramucirumab, IMF-001, Autologous genetically modified ADP-A2M4CD8 cells, Sintilimab, Atezolizumab, Erdafitinib, M6620, DC-CIK, APX005M, BO-112, M1231, Ramucirumab, CYH33, PCA062, CAR-T/TCR-T cells, LUM015, JAB-3068, Niraparib, APG-2449, TAEST16001, CX-2029, S-488210, ZSP1241, VMD-928 300, DF6002, TGR-1202, AV 203, S-588410, Socazolimab, AMG 337, Retifanlimab, RO 7092284, Serplulimab, Cellspan Esophageal implant, CDX-1140, KY1044, NGM120, SGN-B6A, NP-G2-044, ADCT-301, AB308, Epacadostat, SCT-I10A, Larotinib, KN046, Sugemalimab, and others.
  • Esophageal Cancer Segmentation: Phases, Product Type, Molecule Type, Mechanism of Action, Route of Administration

 

Dive deep into rich insights for drugs for Esophageal Cancer Market Drivers and Esophageal Cancer Market Barriers, click here @ Esophageal Cancer Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Esophageal Cancer Executive Summary
  3. Esophageal Cancer: Overview
  4. Esophageal Cancer Pipeline Therapeutics
  5. Esophageal Cancer Therapeutic Assessment
  6. Esophageal Cancer– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Pre-Registration)
  8. Drug Name : Company Name
  9. Drug profiles in the detailed report…..
  10. Last Stage Products (Phase  II/III)
  11. Tucatinib: Seagen
  12. Drug profiles in the detailed report…..
  13. Mid Stage Products (Phase II)
  14. APX 005M: Apexigen
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug Name : Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Esophageal Cancer Key Companies
  21. Esophageal Cancer Key Products
  22. Esophageal Cancer – Unmet Needs
  23. Esophageal Cancer – Market Drivers and Barriers
  24. Esophageal Cancer – Future Perspectives and Conclusion
  25. Esophageal Cancer Analyst Views
  26. Esophageal Cancer Key Companies
  27. Appendix

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Esophageal Cancer drugs?
  • How many Esophageal Cancer drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Esophageal Cancer?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Esophageal Cancer therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Esophageal Cancer and their status?
  • What are the key designations that have been granted to the emerging drugs?

 

Got Queries? Find out the related information of Esophageal Cancer mergers and acquisitions, Esophageal Cancer licensing activities, Esophageal Cancer emerging drugs, and Esophageal Cancer recent trends @ Esophageal Cancer Market Drivers and Barriers

  

About Us

 

DelveInsight’s is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-pipeline-insight-2021

Related Articles